Literature DB >> 32073504

The natural history of alcohol-related liver disease.

Richard Parker1.   

Abstract

PURPOSE OF REVIEW: This review will describe the natural history of alcohol-related liver disease (ArLD) in light of recent data that have synthesized existing knowledge on this topic and described new research cohorts to improve our understanding of progression and outcomes in ArLD. RECENT
FINDINGS: ArLD occurs after a threshold of alcohol consumption, but this threshold is lowered by the presence of comorbid factors of which obesity is the most common. The most common stage of ArLD is alcohol-related steatosis: this is associated with a low rate of progression to cirrhosis (3%/year) and nonliver-related morbidity is more likely (4 versus 1%/year). In contrast, alcohol-related steatohepatitis or cirrhosis is more dangerous with higher rates of both nonliver and liver-related mortality. Hepatocellular carcinoma occurs at approximately 3%/year amongst people with ArLD cirrhosis.
SUMMARY: These data allow an understanding of ArLD to accurately counsel patients and also to guide public health policies. Awareness of the shortcomings of the available data, highlighted in a recent systematic review, will inform the design of further research in particular to describe the multiple interacting factors that may cause ArLD to regress or progress.

Entities:  

Mesh:

Year:  2020        PMID: 32073504     DOI: 10.1097/MOG.0000000000000627

Source DB:  PubMed          Journal:  Curr Opin Gastroenterol        ISSN: 0267-1379            Impact factor:   3.287


  3 in total

1.  Substance use disorder is associated with alcohol-associated liver disease in patients with alcohol use disorder.

Authors:  Augustin G L Vannier; Vladislav Fomin; Raymond T Chung; Suraj J Patel; Esperance Schaefer; Russell P Goodman; Jay Luther
Journal:  Gastro Hep Adv       Date:  2022-03-30

2.  Incidence and Progression of Alcohol-Associated Liver Disease After Medical Therapy for Alcohol Use Disorder.

Authors:  Augustin G L Vannier; Jessica E S Shay; Vladislav Fomin; Suraj J Patel; Esperance Schaefer; Russell P Goodman; Jay Luther
Journal:  JAMA Netw Open       Date:  2022-05-02

3.  Does knowledge of liver fibrosis affect high-risk drinking behaviour (KLIFAD)? protocol for a feasibility randomised controlled trial.

Authors:  Mohsan Subhani; Katy A Jones; Kirsty Sprange; Stefan Rennick-Egglestone; Holly Knight; Joanne R Morling; Doyo G Enki; Andrew Wragg; Stephen D Ryder
Journal:  BMJ Open       Date:  2021-11-03       Impact factor: 2.692

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.